![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
The CPhI Pharma Awards are among the most prestigious recognitions within the pharmaceutical industry. MJR PharmJet, partner of leon-nanodrugs GmbH in drug development received one of this year’s awards for the highly innovative MicroJet Reactor Technology.
leon-nanodrugs is the owner of the MicroJet Reactor Technology for the creation of pharmaceutical nanoparticles and drug delivery systems enabling specific formulations of pharmaceuticals. MJR PharmJet holds a comprehensive patent family covering the technology and collaborates with leon-nanodrugs in the development of innovative drug formulations using leon’s proprietary nanotechnology.
This year’s CPhI awards attracted more than 200 entries in 19 categories. MJR PharmJet brought forward the MicroJet Reactor Technology for the continuous synthesis of nanoparticles under GMP conditions winning the first prize in the ‘Manufacturing Technology and Equipment’ category. This is a strong recognition of the value of the MicroJet Reactor Technology in technology transfer from lab scale to manufacturing scale in manufacturing of nanoparticles.
It is estimated that over 60% of pharmaceutical API’s are poorly soluble in water. leon’s MJR Technology offers formulation options that not only address this issue, but can also lead to a superior profile for the API by increasing bioavailability, reducing inter patient variability or improving onset of action. The one-step, bottom up, continuous production process approach of the MJR technology enables the development of a wide variety of nanoparticle types, tailored particles sizes and is easily scalable.
Dr. Michael Mehler, CEO of leon-nanodrugs GmbH comments: “We congratulate our partner, MJR PharmJet, for receiving such a prestigious award. This is a great testimony of the potential of the unique attributes of the MicroJet Reactor Technology and confirms our vision to generate added value for therapeutic molecules through specific nano-formulations. In addition to MJR PharmJet with our USA based CDMO CoreRx we can offer our pharmaceutical and biotechnology partners access to this innovative technolo
About Leon
Leon-nanodrugs GmbH (Munich) is a nanotechnology-based drug development company focused on the development of novel oral and parenteral formulations and innovative drug combinations. Build on its “network of expertise”, leon-nanodrugs can provide a 360 degree service range – from concept to product approval. By using MJR®-technology leon took the technical leadership in the re-formulation market and is creating patient benefits and economical values to existing drugs. leon works with its Pharma customers through contract development agreements, as well as co-development partnerships. leon has also initiated work on its own internal development projects, concentrating on nanotechnology-based reformulations that offer enhanced clinical and safety benefits.
About MJR Pharmjet
MJR PharmJet is a member of Instillo group which consolidates and supplies administrative support to an independent group of companies which operates over 20 countries worldwide. It has established a strong network and built up a competitive team offering their expert knowledge for a number of national and international companies in a trustworthy working environment. It is a fast growing group with a wide range of pharmaceutical services from development through registration to commercialization which is realised by the companies MJR PharmJet GmbH and Quasaar GmbH. Quasaar takes over the GMP relevant aspects of drug and formulation development and brings the products forward in the path of commercialization.
Contact
Dr. Michael Mehler
Chief Executive Officer
leon-nanodrugs GmbH
Kopernikusstrasse 9
D-81679 München
m.mehler@leon-nanodrugs.com
